The multicenter double-blind, randomized Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) was designed to assess whether ACEI and non-dihydropyridine calcium-channel blocker (CCB), alone or in combination, prevent microalbuminuria in subjects with hypertension, T2D, and normal urinary albumin excretion. This evidence concerns the gene ALB and type 2 diabetes mellitus.